I agree that the NASDAQ listing helps ESPR, that's why I mentioned it in my first post on this topic. I also agree that ESPR is better promoted than RVX, the failures of RVX's management in this regard was the whole point of my first post. That ESPR has fallen by more than twice RVX's market cap and yet ESPR remains, after currency adjustment, at a valuation of roughly 10x that of RVX to me speaks volumes to the fact that either not enough investors know of RVX or that investors do not trust that management will deliver on what it says. In either case management should get their act together as has done the management at ESPR.

For the record my intent was never to promote ESPR as an investment. I think RVX has much more upside as ESPR is already probably close to fairly valued for ph3 success in the context of the market. To give a little more context, right now there are a number of pre-clinical biotechs that have higher valuations than RVX. Pretty sad. In the end, where RVX's valuation will be important is if it needs to raise more cash. Part of Zacks low target price calculation is due to the consideration that if RVX had to raise cash to pay off its' loan, at the current SP this exercise would be extremely dilutive.